See today's BioWorld Asia
To read the full story, subscribe or sign in.

Helixmith points to success in VM-202 phase III-Ib trial, though investors skeptical

Oct. 23, 2019
By Jihyun Kim
HONG KONG – South Korea's Helixmith Co. Ltd. has announced the results of a phase III trial extension testing VM-202 (donaperminogene seltoplasmid), a regenerative plasmid DNA gene therapy candidate, in diabetic peripheral neuropathy (DPN).
BioWorld Asia Clinical Asia-Pacific